SE9202934D0 - Vacciner mot melanom - Google Patents

Vacciner mot melanom

Info

Publication number
SE9202934D0
SE9202934D0 SE9202934A SE9202934A SE9202934D0 SE 9202934 D0 SE9202934 D0 SE 9202934D0 SE 9202934 A SE9202934 A SE 9202934A SE 9202934 A SE9202934 A SE 9202934A SE 9202934 D0 SE9202934 D0 SE 9202934D0
Authority
SE
Sweden
Prior art keywords
peptides
proteins
melanom
vaccine formulations
vaccines against
Prior art date
Application number
SE9202934A
Other languages
English (en)
Swedish (sv)
Inventor
J P Brown
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26676698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9202934(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/007,230 external-priority patent/US5262177A/en
Application filed by Oncogen filed Critical Oncogen
Publication of SE9202934D0 publication Critical patent/SE9202934D0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SE9202934A 1986-02-07 1992-10-07 Vacciner mot melanom SE9202934D0 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82731386A 1986-02-07 1986-02-07
US07/007,230 US5262177A (en) 1986-02-07 1987-01-27 Recombinant viruses encoding the human melanoma-associated antigen

Publications (1)

Publication Number Publication Date
SE9202934D0 true SE9202934D0 (sv) 1992-10-07

Family

ID=26676698

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8700466A SE506024C2 (sv) 1986-02-07 1987-02-06 Melanomassocierat P97 antigen och immunogen komposition
SE9202934A SE9202934D0 (sv) 1986-02-07 1992-10-07 Vacciner mot melanom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SE8700466A SE506024C2 (sv) 1986-02-07 1987-02-06 Melanomassocierat P97 antigen och immunogen komposition

Country Status (18)

Country Link
JP (3) JP2664673B2 (xx)
BE (1) BE1000175A3 (xx)
CH (1) CH675424A5 (xx)
DE (1) DE3703702C2 (xx)
DK (1) DK63287A (xx)
ES (2) ES2012815A6 (xx)
FI (1) FI94836C (xx)
GR (1) GR870195B (xx)
HU (1) HU209144B (xx)
IE (1) IE59597B1 (xx)
IT (1) IT1222359B (xx)
MX (1) MX9203574A (xx)
NL (1) NL8700285A (xx)
NO (1) NO178931C (xx)
NZ (1) NZ219192A (xx)
OA (1) OA08478A (xx)
PT (1) PT84255B (xx)
SE (2) SE506024C2 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821925A1 (de) * 1998-05-15 1999-11-18 Roehnisch Tim Verfahren zur Herstellung einer Zusammensetzung zur Induktion einer tumorspezifischen Immunantwort, sowie Verwendung der Zusammensetzung zur Behandlung von Neoplasien
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
JP4708027B2 (ja) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Also Published As

Publication number Publication date
FI870501A (fi) 1987-08-08
IE59597B1 (en) 1994-03-09
SE8700466D0 (sv) 1987-02-06
HUT43107A (en) 1987-09-28
HU209144B (en) 1994-03-28
DK63287A (da) 1987-08-08
FI94836B (fi) 1995-07-31
IE870319L (en) 1987-08-07
JP2664673B2 (ja) 1997-10-15
IT8719291A0 (it) 1987-02-06
NZ219192A (en) 1991-10-25
DK63287D0 (da) 1987-02-06
GR870195B (en) 1987-06-10
FI94836C (fi) 1995-11-10
NO178931C (no) 1996-07-03
JPH09135692A (ja) 1997-05-27
NL8700285A (nl) 1987-09-01
PT84255B (pt) 1989-11-30
SE506024C2 (sv) 1997-11-03
BE1000175A3 (fr) 1988-07-12
DE3703702C2 (de) 1997-07-10
JPH08280390A (ja) 1996-10-29
CH675424A5 (en) 1990-09-28
OA08478A (fr) 1988-07-29
PT84255A (en) 1987-03-01
IT1222359B (it) 1990-09-05
NO178931B (no) 1996-03-25
NO870475L (no) 1987-08-10
FI870501A0 (fi) 1987-02-06
NO870475D0 (no) 1987-02-06
ES2017258A6 (es) 1991-01-16
ES2012815A6 (es) 1990-04-16
JPS62294698A (ja) 1987-12-22
DE3703702A1 (de) 1988-02-18
SE8700466L (sv) 1987-08-08
MX9203574A (es) 1992-07-01

Similar Documents

Publication Publication Date Title
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
ATE97164T1 (de) Rekombinantes vaccinia-virus mva.
ATE258188T1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
EE9900343A (et) Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
DE3689622D1 (de) Impfstoffe gegen menschliche respiratorische viren.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
SE9202934D0 (sv) Vacciner mot melanom
KR900701291A (ko) 혈호균속 인플루엔자용 백신과 진단검사법
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
NO20041564L (no) Infeksios lakse anemi-virus vaksine
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
EP0293201A3 (en) Method of vaccination for hepatitis b virus
ATE84722T1 (de) Tollwut-lebendimpfstoff.
RU92004487A (ru) Днк, полипептид, вакцина, вектор, микроорганизм, клетка насекомого, реагент, способы лечения и профилактики, способ обнаружения антигенов
DE216901T1 (de) Immunogenes antigen-traeger-proteinkonjugat zur verwendung in impfstoffen gegen malaria.